Crisaborole (trade name Eucrisa) is a nonsteroidal topical medication used for the treatment of mild-to-moderate atopic dermatitis (eczema) in people two years or older. It was approved by U.S. Food and Drug Administration on Dec 14, 2016 and June 6, 2018 by Health Canada.

Property Value
dbo:abstract
  • Crisaborole (trade name Eucrisa) is a nonsteroidal topical medication used for the treatment of mild-to-moderate atopic dermatitis (eczema) in people two years or older. It was approved by U.S. Food and Drug Administration on Dec 14, 2016 and June 6, 2018 by Health Canada. (en)
dbo:alternativeName
  • Eucrisa, (en)
dbo:casNumber
  • 906673-24-3
dbo:chEBI
  • 134677
dbo:drugbank
  • DB05219
dbo:fdaUniiCode
  • Q2R47HGR7P
dbo:kegg
  • D10873
dbo:pubchem
  • 44591583
dbo:thumbnail
dbo:wikiPageEditLink
dbo:wikiPageExtracted
  • 2019-09-14 20:44:04Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 46181068 (xsd:integer)
dbo:wikiPageLength
  • 6812 (xsd:integer)
dbo:wikiPageModified
  • 2019-09-14 20:43:44Z (xsd:date)
dbo:wikiPageOutDegree
  • 28 (xsd:integer)
dbo:wikiPageRevisionID
  • 915701015 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Crisaborole (trade name Eucrisa) is a nonsteroidal topical medication used for the treatment of mild-to-moderate atopic dermatitis (eczema) in people two years or older. It was approved by U.S. Food and Drug Administration on Dec 14, 2016 and June 6, 2018 by Health Canada. (en)
rdfs:label
  • Crisaborole (en)
foaf:depiction
foaf:isPrimaryTopicOf
owl:sameAs
is foaf:primaryTopic of